These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18046446)

  • 1. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
    Yaccoby S; Pennisi A; Li X; Dillon SR; Zhan F; Barlogie B; Shaughnessy JD
    Leukemia; 2008 Feb; 22(2):406-13. PubMed ID: 18046446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
    Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
    Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.
    Moreaux J; Cremer FW; Reme T; Raab M; Mahtouk K; Kaukel P; Pantesco V; De Vos J; Jourdan E; Jauch A; Legouffe E; Moos M; Fiol G; Goldschmidt H; Rossi JF; Hose D; Klein B
    Blood; 2005 Aug; 106(3):1021-30. PubMed ID: 15827134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
    Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
    Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells.
    Nys J; Smulski CR; Tardivel A; Willen L; Kowalczyk C; Donzé O; Huard B; Hess H; Schneider P
    PLoS One; 2013; 8(4):e61350. PubMed ID: 23620746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma.
    Abe M; Kido S; Hiasa M; Nakano A; Oda A; Amou H; Matsumoto T
    Leukemia; 2006 Jul; 20(7):1313-5. PubMed ID: 16617317
    [No Abstract]   [Full Text] [Related]  

  • 7. Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues.
    Eslami M; Schuepbach-Mallepell S; Diana D; Willen L; Kowalczyk-Quintas C; Desponds C; Peter B; Vigolo M; Renevey F; Donzé O; Luther SA; Yalkinoglu Ö; Alouche N; Schneider P
    Proc Natl Acad Sci U S A; 2024 Jul; 121(29):e2404309121. PubMed ID: 38990948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
    Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
    Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
    Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
    Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APRIL is overexpressed in cancer: link with tumor progression.
    Moreaux J; Veyrune JL; De Vos J; Klein B
    BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
    Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
    Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No interactions between heparin and atacicept, an antagonist of B cell survival cytokines.
    Kowalczyk-Quintas C; Willen D; Willen L; Golob M; Schuepbach-Mallepell S; Peter B; Eslami M; Vigolo M; Broly H; Samy E; Yalkinoglu Ö; Schneider P
    Br J Pharmacol; 2019 Oct; 176(20):4019-4033. PubMed ID: 31355456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties.
    Schuepbach-Mallepell S; Das D; Willen L; Vigolo M; Tardivel A; Lebon L; Kowalczyk-Quintas C; Nys J; Smulski C; Zheng TS; Maskos K; Lammens A; Jiang X; Hess H; Tan SL; Schneider P
    J Biol Chem; 2015 Jun; 290(26):16330-42. PubMed ID: 25953898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
    Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
    Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL.
    Kanswal S; Katsenelson N; Selvapandiyan A; Bram RJ; Akkoyunlu M
    J Immunol; 2008 Jul; 181(2):976-90. PubMed ID: 18606649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
    Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
    Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis.
    Qin Q; Chang Y; Wang D; Wu Y; Zhang LL; Wei W
    Int Immunopharmacol; 2011 Dec; 11(12):2167-75. PubMed ID: 21996540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
    Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
    Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.
    Marsters SA; Yan M; Pitti RM; Haas PE; Dixit VM; Ashkenazi A
    Curr Biol; 2000 Jun; 10(13):785-8. PubMed ID: 10898980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
    Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M
    Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.